drugset / Trial / NCT03865953
Oral LAT8881 in Neuropathic Pain
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.
Timeline
- Start
- 2019-04-09
- Primary completion
- 2020-04-19
- Completion
- 2020-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LAT8881 | Protein / enzyme biologic | 30 mg | Oral |